Chemo-Free combo shows promise for CLL patients
NCT ID NCT02666898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a chemotherapy-free combination of two drugs, obinutuzumab and ibrutinib, in 135 people with previously untreated chronic lymphocytic leukemia (CLL). The treatment was given for nine months, and then the next steps were decided based on how much leukemia remained in the bone marrow. The goal was to see if this approach could control the disease without traditional chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
obinutuzumab (GA101) and ibrutinib (Imbruvica)
What this could lead to
If successful, this could point toward a chemotherapy-free treatment option for chronic lymphocytic leukemia that is tailored based on how well the disease responds.
What could go wrong
This is a phase 2 trial with only 135 participants, so results are not definitive. The treatment may not work for everyone, and side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sponsor FILO
Tours, 37054, France